在旧金山J.P.摩根保健大会上介绍癌症药物进展。 
Ascentage Pharma to present cancer drug progress at J.P. Morgan Healthcare Conference in San Francisco.
以癌症治疗为重点的生物制药公司Aspentage Pharma将在2025年1月16日在旧金山举行的J.P.摩根保健大会上介绍其进展和未来计划。 Ascentage Pharma, a biopharmaceutical company focused on cancer therapies, will present its progress and future plans at the J.P. Morgan Healthcare Conference on January 16, 2025, in San Francisco. 该公司由首席执行官Dajun Yang博士领导,拥有强有力的药物候选人渠道,并与Takeda、AstraZeneca和Pfizer等主要制药公司合作。 The company, led by CEO Dr. Dajun Yang, has a robust pipeline of drug candidates and collaborates with major pharmaceutical firms like Takeda, AstraZeneca, and Pfizer. 其主要药物(olverembatinib)被列入中国国家药物偿还清单。 Its lead drug, olverembatinib, is included in China's national drug reimbursement list.
